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There has been an increase in the burden of Clostridioides difficile infection (CDI)1; especially in 
high-risk populations such as patients with inflammatory bowel disease (IBD).2 The prevalence 
of CDI in the IBD population is up to 8-fold higher than comparable controls with increased 
rates of recurrence and CDI-associated mortality.3 Additionally, CDI may induce an IBD flare, 
worsen disease severity and clinical course.4  
 
Fecal microbiota transplantation (FMT) is a guideline recommended therapy for recurrent CDI5; 
however, supportive randomized trials excluded IBD patients. In retrospective trials of IBD 
patients, FMT failure rates had been reported to be approximately 25-30%.6 Additionally, 
Khoruts and colleagues reported that patients with IBD and CDI were more likely to fail FMT,7
leading to further uncertainty regarding  the safety and efficacy of FMT in IBD patients with 
concurrent CDI. Accordingly, we conducted the first prospective study examining the efficacy of 




We conducted an open-label, prospective, single-arm, multicenter cohort study at 4 tertiary care 
FMT referral centers (Brigham and Women’s Hospital, Indiana University, Brown University, 
and Mount Sinai Hospital; NCT03106844). Patients with a confirmed diagnosis of IBD and 2 or 
more confirmed CDI episodes within 12 months, including the most recent episode occurring 
within 3 months, were enrolled. In keeping with CDI clinical guidelines5, polymerase chain 
reaction or glutamate dehydrogenase with toxin enzyme immunoassay were permitted for the 
qualifying CDI episode. Patients with a total or subtotal colectomy, isolated ileal or small bowel 
CD, those pregnant or breastfeeding, those treated with vancomycin or metronidazole for more 
than 60 days, or those that had undergone a prior FMT within 12 months were excluded. 
Baseline IBD and CDI data were collected. All patients underwent a single FMT via 
colonoscopy. Four robustly screened healthy donors were used (Openbiome, Cambridge, USA).8 
 
Stool testing including glutamate dehydrogenase, toxin enzyme immunoassay and polymerase 
chain reaction were performed 1, 8 and 12 weeks post-FMT regardless of symptoms to assess for 
CDI and C. difficile colonization rates. All stool testing was performed at a central laboratory. 
The primary outcome was FMT failure through week 8, defined as diarrhea (3 or more loose 
stools daily for 3 or more days) and stool testing positive for C.difficile via two-step testing using 
glutamate dehydrogenase and toxin enzyme immunoassay. Patients who met the criteria for 
failure underwent a second FMT. Secondary outcomes included C. difficile colonization defined 




Fifty participants were enrolled (August 2017 to October 2019) among which 15 had Crohn’s 
disease (CD) and 35 had ulcerative colitis (UC) (Table 1). The mean age of participants was 43 
years (range 21-91) and the cohort was primarily female (58%). A total of 49 patients received 
treatment. One patient withdrew prior to treatment and was not replaced. Among the 49 
participants, one patient was lost to follow-up after the week 1 visit and was treated as a FMT 
failure. Baseline CDI characteristics: 48% had 2 CDI episodes prior to entry, among which 
87.5% (21/24) were diagnosed via polymerase chain reaction at the qualifying episode; 38% had 
3 confirmed episodes, among which 78.9% (15/19) were diagnosed via polymerase chain 
reaction; and 14% had 4 prior CDI episodes among which 71% were diagnosed via polymerase 
chain reaction (5/7). 
 
Overall, among 49 treated patients, 5 participants (10.2%) were FMT failures, 4 with confirmed 
diarrhea and a positive stool test via glutamate dehydrogenase and toxin enzyme immunoassay 
as well as the patient lost to follow up. Among the failures, 3 patients had 3 prior CDI episodes, 
and 2 patients has 2 prior CDI episodes. Notably, the failures were all primary non-responders 
with failure by week 1 post-FMT. All 4 underwent a second FMT from the same donor and 
achieved clinical cure through week 8. Two additional patients received a second FMT based on 
investigator discretion, but did not meet the criteria for FMT failure (toxin enzyme immunoassay 
and  polymerase chain reaction negative, but ongoing symptoms). Importantly, 45 patients 
(91.8%) experienced C. difficile decolonization 1-week post-FMT and remained polymerase 
chain reaction negative.  
 
Overall the treatment was safe and well-tolerated. Two serious adverse events were reported, 
both were determined to not be treatment-related by the treating physician.  
 
Discussion: Overall, these data suggest the efficacy and safety profile of FMT in IBD-CDI is 
more favorable than previously reported. In this cohort, only 5 patients (10.2%) experienced 
FMT failure, which is significantly lower than the previous failure rates reported in retrospective 
trials, with a mean ~25%.6 This discordant result may be for several reasons. First, patients with 
IBD are prone to diarrhea and patients who remain colonized with ongoing PCR positive stools 
may be mis-diagnosed as a FMT failure. Second, we enrolled patients with their first recurrence 
(2 CDI episodes) in contrast to second recurrence (3 CDI episodes) or further, which is common 
clinical practice. Importantly, we found that the majority of patients were decolonized post-FMT 
which may have public health implications in avoiding spreading C. difficile. 
This study had several limitations. First, this trial was not controlled. We did not feel it was 
appropriate to compare clinical cure rates with standard of care alone given CDI guideline 
recommendations. Additionally, a strong placebo effect seems unlikely in participants with 
prolonged and severe symptoms and an objective laboratory test used for the primary outcome. 
Additionally, we estimated our sample size based on FMT failure rates from retrospective 
studies. We had a significantly lower rate of FMT failure, making subgroup analysis between 
failures and non-failures difficult.  
We undertook the first prospective IBD-CDI trial to follow patients systematically post-FMT 
assessing for CDI eradication and decolonization. We were able to use a central lab and were 
able to perform robust testing on all stool samples for CDI (glutamate dehydrogenase, toxin 
enzyme immunoassay and polymerase chain reaction). Overall, this study suggests FMT for the 
treatment of recurrent CDI in patients with IBD is safe and better tolerated than has been 
previously reported in retrospective studies, and results in a high rate of C. difficile 
decolonization. Additionally, positioning FMT earlier in the treatment course for patients with 
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Table 1: Enrolled Patient Characteristics  
 
Variable  
Female % (n) 58% (29) 
Mean Age 43.0 (range 21-91) 
Crohn’s % (n) 30% (15) 
Colonic 20.0% (3) 
Ileo-colonic 66.7% (10) 
Unknown 13.3% (2) 
UC % (n) 70% (35) 
Proctitis 8.6% (3) 
Left-sided 25.7% (9) 
Pancolitis 60.0% (21) 
Unknown 5.7% (2) 
Race% (n)  
White 94.0% (47) 
Black or African American 4.0% (2) 
Asian 2.0% (1) 
Mean Baseline Calprotectin (SD)  1918.23 +/- 2458.5 
Mean Baseline CRP 5.8 +/- 10.1 
Mean Daily BMs at Baseline 5.2 +/- 4.0 
Mean Baseline Bristol Score 5.5 +/- 1.0 
Mean Baseline Partial Mayo Score 4.2 +/- 2.1 
Mean Baseline HBI score 5.9 +/- 3.5 
 
